Non-nutritional sweeteners effects on endothelial vascular function.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Pergamon Press Country of Publication: England NLM ID: 8712158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3177 (Electronic) Linking ISSN: 08872333 NLM ISO Abbreviation: Toxicol In Vitro Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford ; New York : Pergamon Press, c1987-
    • Subject Terms:
      Blood Vessels/*drug effects ; Endothelial Cells/*drug effects ; Endothelium, Vascular/*drug effects ; Sweetening Agents/*pharmacology; Aspartame/pharmacology ; CX3C Chemokine Receptor 1/metabolism ; Chemokine CX3CL1/metabolism ; Diterpenes, Kaurane/pharmacology ; Endothelium, Vascular/cytology ; Female ; Fructose/pharmacology ; Gene Expression/drug effects ; Glucose/pharmacology ; Glucosides/pharmacology ; Humans ; Hypoxanthine Phosphoribosyltransferase/metabolism ; Neovascularization, Physiologic/drug effects ; Placenta/drug effects ; Placenta/metabolism ; Pregnancy ; Prospective Studies
    • Abstract:
      Aim: Hyperglycemia status induces endothelial dysfunction, although the underlying pathogenic mechanisms are not fully understood. There are several studies connecting sugar/sweetened beverages to the cardiovascular disease. Currently, many sweeteners have been extensively introduced into lifestyle to normalize blood glucose levels without altering the sweet taste. However, there is growing concern for their impact on metabolic health.
      Methods: Human endothelial cells were treated with Glucose, Fructose, Aspartame, Rebaudioside A, Stevioside, or Steviol. Morphological characteristics, in vitro angiogenesis and array gene expression were analyzed.
      Results: High-glucose and fructose concentrations significantly decreased cell features such as angiogenic capability. Interestingly, non-caloric sweeteners did not significantly modified all cell characteristics and they did not compromised cell angiogenic ability. Array gene expression analysis revealed that the chemokine fractalkine (CX3CL1) and the enzyme transferase (HPRT1) were always significantly upregulated and downregulated respectively, after glucose and fructose treatments (P > .05), whereas they were non-differentially expressed with all the other sweeteners. Interestingly, both genes are considered as cardiovascular disease risk biomarkers. Specifically, upregulation of CX3CL1/CX3CR1 occurs in the human placenta and serum levels of the ligand are associated with markers of insulin resistance in GDM.
      Conclusions: Differently from glucose and fructose, steviol glycosides do not damage endothelial cells. Prospective preclinical studies and clinical trials are warranted to confirm the long-term safety of such compounds.
      (Copyright © 2019. Published by Elsevier Ltd.)
    • Contributed Indexing:
      Keywords: Cardiovascular; Diabetes; Endothelium; Sweetener
    • Accession Number:
      0 (CX3C Chemokine Receptor 1)
      0 (CX3CL1 protein, human)
      0 (CX3CR1 protein, human)
      0 (Chemokine CX3CL1)
      0 (Diterpenes, Kaurane)
      0 (Glucosides)
      0 (Sweetening Agents)
      0YON5MXJ9P (stevioside)
      30237-26-4 (Fructose)
      EC 2.4.2.8 (Hypoxanthine Phosphoribosyltransferase)
      IY9XDZ35W2 (Glucose)
      Z0H242BBR1 (Aspartame)
    • Publication Date:
      Date Created: 20191027 Date Completed: 20200608 Latest Revision: 20200608
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.tiv.2019.104694
    • Accession Number:
      31655124